CORDIS
EU research results

CORDIS

English EN
TRAIN-HEART

TRAIN-HEART

Objective

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics
for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long
non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA
molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart
transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery,
specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery
strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness
novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active
in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects
demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and
international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART
fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA
therapeutics to the clinic.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT MAASTRICHT

Address

Minderbroedersberg 4-6
6200 Md Maastricht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 531 239,76

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 252 788,40

UNIVERSITE LYON 1 CLAUDE BERNARD

France

EU Contribution

€ 274 802,04

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 505 576,80

HUMANITAS MIRASOLE SPA

Italy

EU Contribution

€ 522 999,36

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 252 788,40

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 606 345,12

UNIVERSIDADE DO PORTO

Portugal

EU Contribution

€ 475 440,48

MIRABILIS THERAPEUTICS BV

Netherlands

EU Contribution

€ 265 619,88

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 252 788,40

Partners (6)

Sort alphabetically

Expand all

HARTERAAD

SOCIETE EUROPEENNE DE CARDIOLOGIE

DESCIN BV

ACCELERO BIOANALYTICS GMBH

KANEKA EUROGENTEC

EHT TECHNOLOGIES GMBH

Project information

Grant agreement ID: 813716

Status

Ongoing project

  • Start date

    1 June 2019

  • End date

    31 May 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 940 388,64

  • EU contribution

    € 3 940 388,64

Coordinated by:

UNIVERSITEIT MAASTRICHT

Netherlands